{
    "clinical_study": {
        "@rank": "33507", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Experimental", 
                "description": "Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension"
            }, 
            {
                "arm_group_label": "Treatment D", 
                "arm_group_type": "Experimental", 
                "description": "OZ439 (800mg) + TPGS granules for oral suspension"
            }
        ], 
        "brief_summary": {
            "textblock": "A healthy volunteer study to characterise the exposure of the two study medications,\n      following administration of OZ439 + TPGS granules with piperaquine phosphate granules\n      (intended for children) and with piperaquine phosphate tablets (intended for adults).\n      Ideally, to confirm the exposure demonstrated in an earlier bioavailability study."
        }, 
        "brief_title": "Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Parasitemia", 
        "condition_browse": {
            "mesh_term": "Parasitemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy, male or female, any race aged 18-55 years at screening\n\n          -  body mass index of 18-30kg/m2 inclusive; and a total body weight >50kg and up to\n             100kg at screening\n\n          -  Females must have negative pregnancy test at screening, be non-lactating and of\n             non-childbearing potential confirmed by:\n\n               -  natural (spontaneous) post-menopausal defined as amenorrheic for 12 months\n                  without an alternative medical cause with a screening FSH level >25IU/L for post\n                  menopause\n\n               -  irreversible surgical sterilisation by bilateral oophorectomy or bilateral\n                  salpingectomy but not tubal ligation (with or without hysterectomy) at least six\n                  months ago\n\n          -  Must agree to use acceptable methods of contraception Males must use acceptable\n             methods of contraception if the male subject's partner could become pregnant from the\n             time of the first administration of treatment or study medication until 3 months\n             following administration of the last dose of study medication\n\n        One of the following acceptable methods of contraception must be used:\n\n          -  Condom & occlusive cap (diaphragm or cervical/vault caps) with spermicidal\n             foam/gel/film/cream/suppository)\n\n          -  Surgical sterilisation (vasectomy with documentation of azoospermia) and a barrier\n             method (condom or occlusive cap [diaphragm or cervical/vault caps] used with\n             spermicidal foam/gel/film/cream/suppository)\n\n          -  Female partner uses oral contraceptives (combination oestrogen/progesterone pills),\n             injectable progesterone or subdermal implants and a barrier method (as above)\n\n          -  Female partner uses medically prescribed topically-applied transdermal contraceptive\n             patch and a barrier method (as above)\n\n          -  Female partner has had documented tubal ligation (sterilization). In addition, a\n             barrier method (as above) must be used\n\n          -  Female partner has had documented placement of an intrauterine device or system and\n             the use of a barrier method (as above)\n\n          -  True abstinence: when in line with the preferred and usual lifestyle of the subject.\n             Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation\n             methods) and withdrawal are not acceptable methods of contraception. Abstinent\n             subjects must agree use one of the above-mentioned contraceptive methods, if sexual\n             relationships start during the study or up to 90 days after the last dose of study\n             drug\n\n               -  Subjects should not donate egg and sperm from the time of administration of\n                  study medication until 3 months after study medication\n\n               -  Must be capable of understanding and complying with the requirements of the\n                  protocol and must have signed the informed consent form prior to undergoing any\n                  study-related procedures\n\n        Exclusion Criteria:\n\n          -  Male subjects with female partner(s) who is (are) pregnant or lactating from the time\n             of the administration of study medication\n\n          -  Has a clinically significant disease or any condition or disease that might affect\n             drug absorption, distribution or excretion\n\n          -  History of allergic reaction to artemisinin-based compounds, 4-aminoquinolines such\n             as piperaquine or any other clinically relevant allergy to drugs or food\n\n          -  Any clinically significant abnormal laboratory, vital signs or other safety findings\n             as determined by medical history, physical examination or other evaluations conducted\n             at screening or on admission\n\n          -  History or current evidence of any clinically relevant cardiovascular, pulmonary,\n             hepatic, renal, gastrointestinal (excluding appendectomy and cholecystectomy),\n             haematological, endocrinological, immunological, metabolic, neurological,\n             oncological, psychiatric, urological or other disease, or current infection\n\n          -  History of post-antibiotic colitis\n\n          -  Electrocardiogram abnormalities in the 12-lead Electrocardiogram (at screening)\n             and/or 24-hour Holter Electrocardiogram (at screening) which in the opinion of the\n             Investigator is clinically relevant or will interfere with the ECG analysis\n\n          -  History of clinically significant Electrocardiogram abnormalities, or any of the\n             following abnormalities at screening or on admission:\n\n               -  PR >200ms\n\n               -  QRS complex >120ms\n\n               -  QTcB or QTcF >450ms or shortened QTcB or QTcF less than 340ms for males and\n                  females or family history of long QT syndrome or sudden death\n\n               -  Any degree of heart block (such as first, second or third degree\n                  atrioventricular block, incomplete, full or intermittent bundle branch block)\n\n               -  Abnormal T wave morphology / prominent U waves\n\n          -  Positive results in any of the serology tests for Hepatitis B Surface Antigen, anti\n             Hepatitis core antibody, Hepatitis C antibodies, and HIV 1 and 2 antibodies\n\n          -  Confirmed positive results from urine drug screen (amphetamines, benzodiazepines,\n             cocaine, cannabinoids, opiates, barbiturates, and methadone) or from the alcohol\n             breath test at screening and admission\n\n          -  History or clinical evidence of alcohol abuse, or any recreational drug abuse within\n             the 2 years of screening\n\n          -  Mentally handicapped\n\n          -  Participation in a drug trial within 90 days of drug administration\n\n          -  Use of ANY prescription or over the counter medications, within 3 weeks of study\n             medication administration, or vitamins or herbal supplements within 2 weeks of\n             administration of the study drug, unless prior approval is granted. Intermittent use\n             of paracetamol at doses of up to 2g/day is permitted\n\n          -  Use of moderate/strong inhibitors and/or inducers of CYP450 in 4 weeks of drug\n             administration (or at least 5 half-lives of the compound whichever is the longer)\n\n          -  Veins unsuitable for intravenous puncture or cannulation on either arm (veins\n             difficult to locate, access or puncture, or veins with a tendency to rupture during\n             or after puncture)\n\n          -  Transaminases, bilirubin, serum potassium outside normal range at screening or\n             admission\n\n          -  Haemoglobin < lower limit of normal at screening or admission\n\n          -  Donation of >500mL blood in 90 days prior to drug administration\n\n          -  Must be non-smoker for at least three months before screening. \"Tobacco use\" includes\n             smoking and the use of snuff and chewing tobacco, and other nicotine containing\n             products.  May not use any non-nicotine containing smoking cessation aids, e.g.\n             varenicline, for at least three months before screening\n\n          -  Any consumption of grapefruit, Seville oranges, wild grapes, black mulberries,\n             pomegranates as fruit juice, marmalade or as a raw fruit within 7 days prior to\n             dosing of study drug and throughout the study\n\n          -  Any circumstances or conditions, which may affect full participation in the trial or\n             compliance with the protocol\n\n          -  Legal incapacity or limited legal capacity at screening\n\n          -  Vegetarians, vegans or any dietary restrictions conflicting with the study\n             standardised menus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958619", 
            "org_study_id": "MMV_OZ439_13_004", 
            "secondary_id": "2013-003409-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A", 
                "intervention_name": "Piperaquine phosphate tablets (1440mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "intervention_name": "Piperaquine phosphate tablets (960mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment A", 
                    "Treatment B", 
                    "Treatment C", 
                    "Treatment D"
                ], 
                "intervention_name": "OZ439 (800mg) + TPGS granules for oral suspension", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "intervention_name": "Piperaquine phosphate granules for oral solution (960mg)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Piperaquine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "open label", 
            "healthy volunteers", 
            "pharmacokinetic", 
            "parallel group"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Croydon", 
                    "country": "United Kingdom", 
                    "state": "London", 
                    "zip": "CR7 7YE"
                }, 
                "name": "Richmond Pharmacology Ltd."
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "Open Label Pharmacokinetic Study of OZ439 and Piperaquine Following Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in the Fasted State in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Richmond Pharmacology Limited", 
            "last_name": "Ulrike Lorch, MD FRCA FFPM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Blood samples for pharmacokinetics will be collected on Days 1 at the following hours: pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.", 
                "measure": "The observed maximum drug plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 43"
            }, 
            {
                "description": "Blood samples for PK will be collected on Days 1 at the following hours: pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.", 
                "measure": "Area under the plasma concentration versus time curve from time zero to the time of the last measurable concentration post-dose (AUC0-t)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 43"
            }, 
            {
                "description": "Blood samples for pharmacokinetics will be collected on Days 1 at the following hours: pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.", 
                "measure": "The mean maximum exposure (AUC inf)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 43"
            }, 
            {
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Days -2 to 50 +/- 2 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958619"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood samples for pharmacokinetics will be collected on Days 1 at the following hours: pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.", 
                "measure": "Area under the plasma concentration vs. time curve from time zero to 168 hours (AUC0-168)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 43"
            }, 
            {
                "description": "Blood samples for pharmacokinetics will be collected on Days 1 at the following hours: pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.", 
                "measure": "Time to reach maximum plasma concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Days 0 to 43"
            }, 
            {
                "description": "Blood samples for pharmacokinetics will be collected on Days 1 at the following hours: pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.", 
                "measure": "The terminal elimination half-life (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "Days 0 to 43"
            }, 
            {
                "description": "Blood samples for pharmacokinetics will be collected on Days 1 at the following hours: pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.", 
                "measure": "The terminal elimination rate constant (\u03bbz)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 to 43"
            }, 
            {
                "description": "Triplicate 12-lead ECG will be measured at screening, on admission (Day -2), Day 1 pre-dose, 2, 4, 6, 8, 12, 24 (Day 2), 36, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose, and at follow-up (Day 50 +/- 2 days).", 
                "measure": "Triplicate 12-lead ECG", 
                "safety_issue": "Yes", 
                "time_frame": "Days -2 to 50 +/- 2 days"
            }
        ], 
        "source": "Medicines for Malaria Venture", 
        "sponsors": {
            "collaborator": {
                "agency": "Richmond Pharmacology Limited", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Medicines for Malaria Venture", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}